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Left ventricular assist devices (LVADs) are approved as
“destination therapy” (permanent use without plans for
transplantation) in individuals with advanced heart failure
who are not candidates for a cardiac transplant; as such,
these devices are increasingly being used in older adults.
Although LVADs have been shown to increase quality of
life and survival, the associated treatment burdens and
complications deserve careful consideration. The current
study illustrates myriad clinical challenges that can arise
during long-term mechanical support using an older adult
case history. Current data on LVAD use in older adults is
reviewed, and a discussion of relevant points to consider
before LVAD implantation in older adults, including
advance care planning, assessment of gait and cognition,
and the potential for substantial caregiver burden, is
undertaken. J Am Geriatr Soc 60:145–150, 2012.
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Originally indicated as a bridge to transplantation, leftventricular assist devices (LVADs) have become more
common as elective, permanent “destination therapy”
(DT) for individuals with advanced heart failure who
are not eligible for cardiac transplantation. “Destination
therapy” means permanent implantation of an LVAD
without subsequent plans for cardiac transplantation. In
this regard, DT can be thought of as a definitive therapy
(as opposed to the use of an LVAD as a temporary
therapy before heart transplant) that is potentially life
sustaining or life prolonging for individuals with
advanced heart failure. Recent studies suggest positive
effects of DT on symptom management, quality of life,
and functional capacity, prompting consideration of
mechanical circulatory support as a viable treatment
option for individuals with advanced heart failure seek-
ing palliation. Given the high prevalence of advanced
heart failure in older adults,1 coupled with dramatic
advances in LVAD technology, it is not surprising that
the mean age of individuals undergoing LVAD place-
ment has also increased.2 For these reasons, clear guid-
ance regarding the use DT in older adults that addresses
risks, benefits, and burdens is imperative.
The current article presents an instructive case that
prompts discussion of recipient selection for LVAD place-
ment in an effort to better identify older adults who are
likely to benefit from this therapy and to recognize those
with a low likelihood of survival or improvement in qual-
ity of life. A review of LVAD basics, along with potential
benefits, risks, and treatment burdens, in older adults is
undertaken, keeping in mind that an important challenge
to understanding current practices is the dynamic nature
of this rapidly evolving technology.
CASE SUMMARY
Mr. J was a 70-year-old man who presented with a past med-
ical history of a previous stroke and residual right-sided
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weakness, a history of two mechanical falls in the past year,
extensive coronary artery disease resulting in advanced con-
gestive heart failure refractory to maximal medical manage-
ment, and associated poor endurance. After comprehensive
evaluation, he underwent placement of a durable, implant-
able LVAD on January 21, 2009, intended as definitive ther-
apy for his advanced heart failure. After an extended
hospital course complicated by postoperative delirium, he
was discharged to subacute rehabilitation on Postoperative
Day 41. Although his cognition improved during rehabilita-
tion, he continued to require substantial assistance with
activities of daily living upon discharge home from subacute
rehabilitation because of deconditioning and gait instability.
With close follow-up with the LVAD team, Mr. J was able to
live at home for approximately 10 months. Although depen-
dent on his wife for many of his care needs, especially the
care related to his LVAD, he gained symptomatic improve-
ment in his dyspnea and fatigue.
Approximately 10 months after LVAD implantation,
he attempted to rise from a seated position, tripped, and
fell, dislodging his LVAD driveline in the process. He
called out to his wife, who found him unresponsive on the
floor. She retrieved the LVAD backup controller and con-
nected it. He was disconnected from pump for 6 minutes.
Several minutes later, emergency medical services arrived
and initiated cardiopulmonary resuscitation. He was trans-
ported to a local hospital and was later transferred to the
original implanting center in an air ambulance, where he
stabilized.
This episode left him with significant anoxic brain
injury. He was minimally responsive for several days, fol-
lowed by some improvement in mentation, but episodes of
confusion persisted. He also exhibited combative behavior
requiring behavioral and pharmacological management.
His family, although devastated, remained hopeful for
even a modest recovery so that he might be able to return
home. He was discharged to subacute rehabilitation, where
he required close supervision because of residual cognitive
impairment from the anoxic episode. Despite best efforts,
there were several inconsistencies in nursing care in the
subacute facility because of lack of familiarity with LVADs
that resulted in rehospitalization.
During the next year, Mr. J lived at home, with his
wife as his primary caregiver, providing 24-hour supervi-
sion and personal care, with intermittent help from their
adult children. He remained severely cognitively and physi-
cally impaired, with complete dependence in all activities
of daily living. His care needs and medical expenses
resulted in considerable financial burden for his family.
His wife had stopped working to care for him, and their
finances were such that they were unable to hire any out-
side help. During this year, he was hospitalized seven
times. Because of his continued overall decline, repeated
hospitalizations, and substantial caregiver stress on the
part of his wife, the geriatric medicine and palliative care
teams were consulted and provided input on several occa-
sions. His wife and sons were initially reluctant to enter-
tain the idea of hospice because of deeply held cultural
beliefs, but as he continued to decline, his family eventu-
ally accepted hospice services, and he died at home
2 weeks later.
DISCUSSION
Overview
An LVAD, the most common type of durable mechanical
circulatory assist device, is a mechanical pump that provides
support to the left ventricle to maintain adequate blood flow
in individuals with advanced heart failure. LVADs require
surgical implantation through a median sternotomy and
consist of an internal pump with a percutaneous lead con-
necting to an external controller. The external controller
requires constant connection to a power source (batteries or
electrical line power source). LVADs generally fall into two
types: pulsatile flow and continuous flow. The first-genera-
tion pulsatile-flow devices were designed to mimic human
hemodynamics by generating pulsatile circulation. These
devices are larger, with multiple moving parts that can wear
out, and have been associated with higher rates of complica-
tions and higher mortality than newer devices. The smaller,
quieter, second-generation devices using continuous-flow
technology provide more durability because they have fewer
moving parts, allow for implantation into recipients with a
smaller body size, and have resulted in longer survival than
the first-generation devices.2,3
Individuals being considered for LVAD implantation
are considered to fall into one of several categories. The
two main categories include bridge to transplant (BTT)
and destination therapy (DT). Another category, called
“bridge to candidacy” is designated for those receiving
LVADs in whom a transplant might be considered in the
future, depending on stability after the LVAD placement.2
The decision regarding DT versus BTT can be a dynamic
process, with recipients moving between groups. For
instance, some recipients feel so well after LVAD place-
ment that they decline transplant. Others begin as trans-
plant candidates but are no longer felt to be appropriate
after device placement.
Before Food and Drug Administration approval of
LVADs for DT, many older adults, including Mr. J, would
not have been considered for LVAD implantation because
the approved indication was primarily BTT. Although
there is not a firm age limit for heart transplantation, there
is an effective limit based on the overall clinical picture,
and rarely would someone in their 70s be considered for
transplant. In a sense, the expansion of LVAD indications
to include DT has effectively removed this built-in age
deterrent, opening the door to implantation in much older
(and frailer) individuals with advanced heart failure.
Current data from the Interagency Registry for Mechani-
cally Assisted Circulatory Support (INTERMACS) registry,
an ongoing National Heart Lung and Blood Institute–
sponsored collaborative database of LVAD implantations
in the United States,2 indicates that there has been a
dramatic increase in the number of people receiving DT in
2010 from previous years.2 The mean age of individuals
undergoing DT from June 2006 to January 2010 was 61.7
(range 23–82), compared with 52.7 (range 19–88) for indi-
viduals receiving LVADs for all other indications.2 With
rapidly evolving technology, and with DT becoming avail-
able in many centers (69 centers across the United States
have been designated DT centers by CMS),2 a continued
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increase in the numbers of older adults considered for this
therapy can be expected.
Outcomes
With optimal medical management, individuals with
advanced heart failure undergoing chronic inotropic
therapy have a reported 6-month baseline mortality of
almost 50%.4 Of individuals who are not deemed eligible
for cardiac transplantation, DT has been shown to extend
life and to improve certain quality-of-life (QOL) measures.
These outcomes appear to be improving, particularly in
individuals receiving the newer continuous-flow LVADs, as
demonstrated in the HeartMate II (Thoratec Corp., Pleas-
anton, CA) destination therapy trial5 and the most recent
INTERMACS registry data.2 Although the 1- and 2-year
survival rates for participants in the HeartMate II trial
(comparing continuous-flow devices with previously
approved pulsatile devices in individuals ineligible for
heart transplant) were 68% and 58%, respectively,5 fur-
ther experience with newer continuous-flow devices has
resulted in a 1-year survival rate of 74%.2 This improve-
ment in survival is thought in part to reflect recipient selec-
tion, with current trends moving toward implanting
LVADs into less-sick individuals, somewhat earlier in the
trajectory of advanced heart failure.6 In addition, age
alone has recently been identified as an important factor in
predicting clinical outcomes. Older age (70 vs 60) has
shown to be an independent predictor of death throughout
the duration of LVAD therapy.2 Conversely, younger age
is emerging as an important predictor of who will thrive
clinically over the long term with LVAD support.7
With better recipient selection, it has been proposed
that individuals with advanced heart failure might benefit
from prolonged survival and enhanced QOL with LVAD
therapy, despite its burdensome nature.8 Substantial
improvements in QOL have been reported, especially with
the newer continuous-flow devices,9 although these QOL
outcomes for older DT recipients have not been analyzed
separately. Despite this, clinically meaningful improve-
ments in heart failure–related QOL measures using the
Minnesota Living with Heart Failure Questionnaire10 and
the Kansas City Cardiomyopathy Questionnaire11 were
seen in DT recipients in the HeartMate II trial.8,9 Improve-
ments in functional status measures were also observed, as
measured using New York Heart Association (NYHA)
functional class, metabolic equivalents (METs), and 6-min-
ute walk test.9 Whereas most participants had NYHA
Class IV symptoms at baseline, 80% of surviving DT
recipients improved to NYHA Class I or II 6 months
after LVAD implantation. Although substantial improve-
ment in 6-minute hall walk test was also reported, only
34% of participants were able to perform the test at base-
line.9
In light of these improvements in survival and heart
failure–related QOL parameters, it is important to examine
the nature and frequency of durable mechanical support
device complications and ongoing treatment burdens as they
relate to older adults. As illustrated in part by the current
case, relevant outcomes in older adults also include QOL as
related to treatment burden and complications as well as
psychological and cognitive status. Caregiver burden, place
of care, and overall financial burden to individuals, families,
and society are also important considerations.
Perioperative and long-term complications of DT
therapy are common (Table 1). Stroke, infection, bleeding,
and device malfunction or failure requiring reoperation are
recognized complications and substantial sources of
morbidity and mortality, especially early after device
implantation.5 Stroke and infection appear to be particu-
larly common and can be devastating. Hypercoagulability,
along with intermittent low-flow states can increase the risk
of embolic stroke, transient ischemic attacks, and hypoxia
with associated delirium. Although advanced heart failure
alone is thought to contribute to cognitive deficits,12
impairments in neurocognitive function, including delirium,
have been noted in approximately one-quarter to one-third
of individuals after LVAD implantation in small observa-
tional studies.13,14 With the newer continuous-flow devices,
early observations are consistent with trends toward
improvements in executive functioning and memory 1 and
6 months after LVAD implantation without decline in
other domains on neuropsychiatric testing.15 Although the
possibility of a lower incidence of delirium and other
neurocognitive deficits with newer devices may be antici-
pated, these results need to be interpreted with caution
because they are not reported specifically in elderly adults
receiving LVADs.
Another important consideration in older adults is
the reported greater incidence of bleeding (gastroin-
testinal bleeding in particular) observed more recently with
continuous-flow LVADs.6 Individuals with continuous-flow
devices universally require long-term anticoagulation,
which may contribute to greater bleeding risk postopera-
tively and after discharge.
Other potential treatment burdens include the special
attention needed for the care of percutaneous drivelines
and the need for continued external power supply. As the
current case illustrates, attention to protecting the driveline
from trauma must be paid at all times to avoid disconnec-
tion or mechanical malfunction. Living with an LVAD can
result in some restrictions in position and decreased mobil-
ity due to the presence of the driveline and external power
supply. Not surprisingly, the day-to-day care and atten-
tion that the percutaneous driveline demands can be
Table 1. Complications Observed in Individuals with
Continuous-Flow Left Ventricular Assist Devices
(LVADs) in the Heartmate II Destination Therapy Trial
at 24 Months (N = 133)5
Subgroup n (%)
LVAD-related infection 47 (35)
Sepsis 48 (36)
Bleeding requiring surgery 40 (30)
Stroke 24 (18)
Ischemic 11 (8)
Hemorrhagic 15 (11)
Other neurological event* 29 (22)
Rehospitalization 107 (94)
Pump replacement
†
12 (9)
* Transient ischemic attacks and events other than stroke.
† Due to percutaneous lead damage.
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problematic for frail older adults, who are assumed to
have low functional and cognitive reserve.
Adherence to a complex treatment regimen is compul-
sory and also potentially burdensome. This includes the
need to understand and respond to LVAD system signals,
adhere to infection precautions, and maintain close follow-
up with heart failure specialists in LVAD centers that may
be distant from home. In contrast to individuals receiving
an LVAD as a BTT, individuals and their caregivers take
on this substantial change in lifestyle as a permanent
change for the duration of the individual’s life. Not sur-
prisingly, adjustment disorder and major depression have
been noted to occur with greater prevalence after LVAD
implantation.13,14,16
Participant Selection and Considerations in Older
Adults
For any individual being considered for potential LVAD
therapy, current standards call for an extensive, multidisci-
plinary, preoperative assessment by a team that includes, at
a minimum, a heart failure physician, a dietitian, and a
pharmacist.3 Careful assessment of an individual’s medical
status is undertaken for optimal recipient selection and tim-
ing of LVAD implantation in an effort to minimize periop-
erative risk. Initially, the nature of the individual’s heart
failure status is risk stratified using a scoring system based
on outcomes from the INTERMACS registry.2 The most-
robust data support consideration for LVAD placement in
individuals who are stable on inotropic support and not
those who have cardiogenic shock or other high-risk status,
including major end-organ failure, prolonged mechanical
ventilation, sepsis, and hemodynamic instability.3
Once an individual is determined to be a potential
LVAD candidate based on heart failure status, further
assessment of perioperative risks and potential longer-term
treatment benefits and burdens is undertaken. In addition
to preoperative assessment of multiple parameters, includ-
ing hemodynamics, hepatic and renal function, hematolog-
ical and coagulopathic measures, and nutritional status, it
is suggested that the individual’s social network, including
adequacy of caregiver support, housing, transportation,
and overall adherence to treatment, be assessed and
factored into any decision regarding candidacy.3 Current
standards also call for the assessment of the presence of
psychiatric disorders, history of substance abuse, or any
neurological condition that might impair the individual’s
ability to care for the external LVAD system,3 although
specific assessment protocols and tools used for neurologi-
cal, functional, psychiatric, and psychosocial assessments
are not standardized across centers.
The current case highlights several points worth
exploring as they relate to older adults. At baseline, the
individual described above had evidence of gait impair-
ment due to a previous stroke, sustaining two mechanical
falls in the year before LVAD implantation. Currently
accepted Centers for Medicare and Medicaid Services DT
criteria17 are based on cardiopulmonary physiological
parameters (Table 2). Neither these criteria nor current
expert consensus on recipient selection for DT3 formally
address whether the presence of certain geriatric syn-
dromes, such as gait impairment, might preclude LVAD
eligibility. Although falls from multiple causes are common
in older adults,18 older adults with heart failure have a
greater prevalence of geriatric conditions including gait
impairment and are more likely to sustain an injury when
falling.19 In retrospect, perhaps this individual’s preexisting
gait impairment and history of falls could have been con-
sidered a contraindication to LVAD implantation, given
his subsequent fall resulting in driveline disconnection and
anoxic encephalopathy. Although he underwent a full
physical therapy evaluation as part of his pre-LVAD
assessment, his gait impairment (hemiparesis necessitating
a cane) was deemed to be mild and did not affect his can-
didacy for DT. It might be argued that improvements in
exercise tolerance and ambulation, as evidenced by docu-
mented improvements in the 6-minute hall walk test noted
in the HeartMate II DT trial, may be reasonable expecta-
tions in individuals who are ambulatory before receiving
LVAD destination support.9
As with most geriatric syndromes and conditions, the
role of impaired gait and balance is underexplored but
remains an important area for investigation as greater
numbers of older adults are offered LVAD support. Slow
gait speed has recently been found to be a useful predictor
of mortality and major morbidity in older adults undergo-
ing cardiac surgery.20 This simple measure, defined as time
taken to walk 5 m for longer than 6 seconds, has been
found to be a useful global measure to detect frailty in
individuals with multiple comorbidities and deserves fur-
ther study as a potential useful predictive tool for older
adults being considered for DT.
As illustrated with Mr. J’s case, primary caregivers
and family members of individuals with DT can experi-
ence prolonged caregiver stress, with the need for vigi-
lant monitoring, especially in individuals who have
sustained a near-catastrophic complication such as Mr. J
or other common complications such as stroke or infec-
tion. Little is known about the experience of caregivers
caring for individuals with DT, in which intensive care-
giving needs can be prolonged. One qualitative study
characterizing the experience of caregivers for people
with BTT describes recurrent themes best characterized
as “commitment,” indicating that they would do it all
again; “sacrifice,” in which they describe social isolation,
loss of employment, and financial strain; and “moving
beyond,” in which they are able to adapt and accept
their intensive caregiving roles.21 These experiences and
themes may not be fully applicable to caregivers of DT
recipients, because the BTT is usually viewed as a situa-
tion to be endured temporarily.
Evidence of overall cost-effectiveness of mechanical
support is uncertain at best. The rapid progress in LVAD
technology over the last few years, characterized by docu-
mented improvements in survival and heart failure–related
QOL measures, limit current assessments of cost-effective-
ness. A 2008 study analyzing outcomes and costs of
LVADs in Medicare beneficiaries concluded that LVADs
were associated with substantial early mortality, morbid-
ity, and high costs.22 That the newer continuous-flow
devices were not included in this study appears to be a
major limitation. Further analysis is needed given the
recent dramatic shift to the almost-exclusive use of the new-
est-generation devices that most centers are implanting,
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although as Medicare spending associated with procedures
and device implantation comes under greater political and
public scrutiny,23 the high societal costs associated with
LVAD support also need to be carefully weighed.
An important aspect of the pre-LVAD evaluation
includes cognitive assessment to ensure adequate decision-
making and a true informed consent process.24 Some pro-
pose full neurocognitive testing to detect impairments in
executive function that can affect complex treatment needs
and ability to perform instrumental activities of daily liv-
ing.25 True informed consent includes discussing benefits
and treatment burdens of all options (Table 3).24,26
General consensus dictates that the informed consent
process take place directly with the individual and not a
surrogate decision-maker, because LVADs are not curative
and less-burdensome therapies exist.24
Greater use of DT in older adults provides important
opportunities for greater partnership between colleagues in
geriatric medicine and palliative care, with specialized
heart failure teams providing longitudinal care for individ-
uals receiving mechanical support. Such opportunities for
collaboration exist during pre-LVAD evaluation and dur-
ing support, when complications and comorbidities are
likely to affect an individual’s QOL. Formal calls for
greater participation of palliative care and geriatric medi-
cine teams in the care of individuals receiving destination
mechanical support have been made.24,26,27
Although a full discussion of the dying process of indi-
viduals receiving LVAD therapy is beyond the scope of this
article, it is noted that a thoughtful dialogue about
advance care planning should begin before LVAD implan-
tation.26,27 The pre-LVAD evaluation must include a
detailed discussion of individual goals and values, specifi-
cally anticipating the situation in which LVAD therapy no
longer supports a level of function or QOL that is accept-
able to the individual. Although it is not possible to
predict exactly how this situation may arrive, most indi-
viduals know what core life functions are most important
to them, for example, continuing to contribute to work,
family, or social roles; being able to live at home or at
least outside the hospital; or simply being able to interact
with loved ones and appreciate even passive participation
in meaningful activities. Goals can change over time as an
individual adapts to changing capacity, so this discussion
should be revisited regularly. Eliciting such information
before LVAD placement is not meant to predetermine spe-
cific treatment decisions but rather to establish a frame-
work to ensure that ongoing treatment plans are helping
an individual live the way he or she wants to live.
At the University of Michigan Hospital, all recipients
undergo detailed pre-LVAD evaluation by a multidisciplin-
ary team in a process that is identical to the assessment
before heart transplantation. Goals of therapy are dis-
cussed extensively, as is the need for a 24 hour compan-
ion. Advance care planning, including discussions about
assigning a durable power of attorney for healthcare deci-
sion-making, is reviewed with every individual. In addition
to establishing traditional advance directives, efforts to
assist individuals and their surrogates with “in the
moment” decision-making have been proposed and appear
especially useful for LVAD-related decision-making.28
Additional steps may also assist with difficult decisions; with
early involvement of palliative care before implantation,
some programs encourage an LVAD candidate to consider a
“preparedness plan” or palliative care plan when treatment
burdens of ongoing support outweigh its benefits.26,29 In
this way, the groundwork is laid for when complications
might arise. Ongoing palliative care involvement can help
Table 2. Centers for Medicare and Medicaid Services
Criteria for Left Ventricular Assist Device (LVAD)
Destination Therapy16
New York Heart Association Class IV for  90 days
Life expectancy <2 years
Not a candidate for transplantation
Symptoms have not responded to optimal medical management
for >60 days
Left ventricular ejection fraction <25%
Peak oxygen consumption of <12 mL/kg per minute or need
for continuous intravenous inotropes
Appropriate body size ( 1.5 m²) to support the LVAD implantation
Table 3. Elements of Informed Decision-Making in Discussions About Left Ventricular Assist Device (LVAD) Des-
tination Therapy (DT): Questions to Ensure That Individuals with Advanced Heart Failure Are Making Informed
Decisions3,11
Have all treatment options been discussed, including continued optimal medical management (often with inotropic support), DT,
or palliative care?
What is the individual’s understanding of his or her disease?
What are the individual’s goals of care? Survival? Improved quality of life? What are the individual’s hopes?
Does the individual have a clear understanding of the common complications of DT, including infection, stroke, bleeding, need
for anticoagulation, and device malfunction, and what the individual will typically experience?
Does the individual have advance directives in place, including a designated durable power of attorney for health care and a concise plan
of individual preferences for anticipated device-related complications?
Does the individual have an accurate understanding of day-to-day life with an LVAD? Has he or she talked with an LVAD recipient?
Can the individual articulate agreed-upon guidelines for deactivating his or her LVAD if treatment burdens outweigh benefits or if the
situation appears futile? Has the role of palliative care and symptom management near the end of life been discussed?
Have criteria for device change-out been discussed with the individual, including a discussion of when this would not be offered?
Have the individual and caregiver(s) received appropriate counseling regarding the substantial role of the caregiver; the need for a
back-up caregiver to be available; the responsibilities of the caregiver pertaining to the need to manage the device monitors, alarms,
and backup controls; and risk of significant caregiver burden?
Do the individual and caregiver understand the nature of the potential long-term financial burden often associated with LVAD destination therapy?
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with symptom management and with transitioning to device
deactivation to allow natural death in some cases.26
Mr. J’s case highlights the complex nuances of DT for
an older adult who was able to derive symptomatic benefit
from DT for a number of months but then sustained treat-
ment complications that included markedly poorer cogni-
tion and impaired physical function. It raises additional
ethical questions about continuing LVAD therapy despite
substantial treatment burden and the possibility of futility.
Finally, the case underscores the substantial caregiver bur-
den and financial strain that can befall those caring for
individuals dependent on technologic therapies such as
LVADs. As such interventions become more commonplace,
these challenges will persist. Routine assessment of gait,
functional status and cognition, degree of caregiver sup-
port, advance care planning, and early involvement of pal-
liative care should be conducted in all older adults being
considered for DT.
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